{"id":"nifedipine-controlled-release-tablets","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Flushing"},{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL193","moleculeType":"Small molecule","molecularWeight":"346.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nifedipine selectively blocks L-type calcium channels in the cell membrane, preventing calcium-dependent contraction of vascular smooth muscle. This leads to peripheral vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand. The controlled-release formulation provides sustained drug delivery over 24 hours, enabling once-daily dosing with more stable blood pressure control.","oneSentence":"Nifedipine is a calcium channel blocker that reduces calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and decreased blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:35.072Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT06501651","phase":"PHASE4","title":"Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2024-08-01","conditions":"Essential Hypertension, Type 2 Diabetes, Nephropathy","enrollment":297},{"nctId":"NCT04349124","phase":"PHASE4","title":"Persistent Postpartum Hypertension Pilot Trial","status":"TERMINATED","sponsor":"Duke University","startDate":"2020-08-25","conditions":"Hypertension in Pregnancy","enrollment":12},{"nctId":"NCT05711810","phase":"PHASE4","title":"Medicine-induced Cardiac Hemodialysis on COVID-19","status":"COMPLETED","sponsor":"Yang I. Pachankis","startDate":"2023-01-02","conditions":"Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines","enrollment":1},{"nctId":"NCT03194633","phase":"","title":"Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-10","conditions":"Hypertension","enrollment":871},{"nctId":"NCT03695107","phase":"","title":"Clinical Study on the Effect of PTH on CYP3A4 Activity","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2019-10-02","conditions":"Chronic Kidney Diseases","enrollment":200},{"nctId":"NCT03245307","phase":"PHASE1","title":"A Study To Test The Effect Of Apatinib On P450 Enzymes","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-08-22","conditions":"Cytochrome P450 Interaction","enrollment":20},{"nctId":"NCT02357615","phase":"PHASE4","title":"Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure","status":"UNKNOWN","sponsor":"Shanghai Shyndec Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Essential Hypertension","enrollment":244},{"nctId":"NCT02031861","phase":"PHASE4","title":"Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Shyndec Pharmaceutical Co., Ltd.","startDate":"2014-02","conditions":"Essential Hypertension","enrollment":38},{"nctId":"NCT01030081","phase":"PHASE4","title":"Amlodipine Prevents Morning Blood Pressure Surge Study","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-10","conditions":"Hypertension","enrollment":510},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT01021501","phase":"PHASE4","title":"The Pharmacokinetics of Nifedipine Controlled Release Tablets in Hypertensive Patients on Hemodialysis","status":"UNKNOWN","sponsor":"Guangzhou First People's Hospital","startDate":"2009-12","conditions":"Hypertension on Chronic Maintenance Hemodialysis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ENCEPHALOPATHY"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":2,"reaction":"MYELOSUPPRESSION"},{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"AORTIC DISSECTION"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"CEREBRAL INFARCTION"}],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalat GITS"],"phase":"marketed","status":"active","brandName":"nifedipine controlled release tablets","genericName":"nifedipine controlled release tablets","companyName":"Guangzhou First People's Hospital","companyId":"guangzhou-first-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nifedipine controlled release tablets are a small molecule medication used to treat essential hypertension and hypertension. They are also studied for their potential effects on chronic kidney disease, particularly in combination with Nephropathy Formula No. 1.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}